LUCID CAPITAL MARKETS Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $30.
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $30.